What is Mologic?
Mologic is a leading innovator in the development of rapid diagnostic products and technology. Since re-establishing its independence in 2014, the company has successfully advanced a portfolio of 10 products to pre-market evaluation, with three receiving CE mark approval in 2016. Mologic's product pipeline is set for further launches in 2017 and 2018, including the world's first respiratory disease exacerbation monitor. Beyond human healthcare, Mologic actively pursues programs in large animal disease diagnostics and vaccine innovation, leveraging technological advancements from its human sector work. The company also provides high-value contract partnering projects for national and international clients, supported by its ISO13485 certified low-volume manufacturing facility. This comprehensive service offering spans from initial concept to initial product volumes, with capabilities for high-volume manufacturing, distribution, and regulatory support through professional partnerships.
How much funding has Mologic raised?
Mologic has raised a total of $14.9M across 4 funding rounds:
Private Equity
$4.6M
Series A
$4.6M
Grant
$4.8M
Series B
$915K
Private Equity (2015): $4.6M with participation from Calculus Capital
Series A (2015): $4.6M led by Calculus Capital
Grant (2016): $4.8M supported by Bill & Melinda Gates Foundation
Series B (2018): $915K featuring Innovate UK
Key Investors in Mologic
Calculus Capital
Calculus Capital is a London-based investment manager specializing in tax-efficient growth capital for UK smaller companies. They manage venture capital trusts (VCTs) and enterprise investment scheme (EIS) funds, focusing on high-growth technology, healthcare, and creative industries businesses.
Bill & Melinda Gates Foundation
The Bill & Melinda Gates Foundation is a global organization dedicated to improving health and reducing poverty, often investing in innovative solutions for public health challenges.
Calculus Capital
Calculus Capital is a London-based investment manager specializing in tax-efficient growth capital for UK smaller companies. They manage venture capital trusts (VCTs) and enterprise investment scheme (EIS) funds, focusing on high-growth technology, healthcare, and creative industries businesses.
What's next for Mologic?
The recent major strategic investment in Mologic signals a pivotal phase for the company, likely focused on scaling its manufacturing capabilities, expanding its product portfolio into new markets, and accelerating the commercialization of its diagnostic technologies. With a strong foundation in both human and animal health, and a proven track record of product development and regulatory approvals, Mologic is well-positioned to capitalize on the growing demand for rapid and accurate diagnostic solutions. Future strategic initiatives may involve further research and development into infectious disease monitoring, as well as exploring new applications for its diagnostic platforms in emerging healthcare sectors. The company's ability to secure significant capital indicates strong investor confidence in its innovative approach and its potential for substantial market impact.
See full Mologic company page
